Skip to main content

Table 1 Demographic and clinical data for ALS patients (n = 11) and healthy controls (n = 11) enrolled for Agilent Human Whole Genome 4 × 44k Array analysis

From: Microarray analysis of peripheral blood lymphocytes from ALS patients and the SAFE detection of the KEGG ALS pathway

Clinical Data at Time of Collection ALS patients Healthy controls
Mean age ± SD 53.8 ± 13 52.2 ± 11
Female 6 9
Male 5 2
Bulbar onset 2 -
Limb onset 8 -
Generalized 1 -
ALSFRS-R <24 5 -
ALSFRS-R >24 6 -
Onset of weakness ≤1 yr 4 -
Onset of weakness 1-5 yrs 4 -
Onset of weakness >5 yrs 3 -
Mean age of onset ± SD 47.2 ± 18 -
Death <3 yrs post-onset 3 -
Death >5 yrs post-onset 2 -
Mean age of death (n = 5) ± SD 62.2 ± 12 -
  1. Three subjects with an ALSFRS-R >24 died within three years (1.5, 2, and 2.5 years) following ALS onset, and two others with an ALSFRS-R <24 died beyond 5 years (7.5 and 9.5 years). Some ALS patients were treated with riluzole (5 out of 11) and taking dietary supplements (7 out of 11) compared to healthy controls which are not matched in this regard. SD is standard deviation.